Acurx Implements 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing

Acurx Pharmaceuticals (ACXP) has implemented a 1-for-20 reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing status. The consolidation will reduce the total number of outstanding common shares from 30.7 million to 1.5 million. Despite its innovative focus, the company faces significant financial challenges, including no revenue growth, negative return metrics, and a poor Piotroski F-Score. Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company developing antibiotics targeting Gram-positive bacterial infections.

Title: Acurx Pharmaceuticals Announces Reverse Stock Split to Meet Nasdaq Listing Requirements

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) has announced a significant corporate action aimed at maintaining its listing on the Nasdaq Capital Market. The company has approved a 1-for-20 reverse stock split, which will take effect at 4:01 p.m. Eastern Time on August 4, 2025, and trading will resume on August 5 on a split-adjusted basis [1].

The reverse stock split is designed to boost the per-share trading price of Acurx's common stock, enabling the company to regain compliance with the Nasdaq minimum bid price requirement. This requirement is crucial for maintaining the company's listing status on the exchange [2].

The reverse stock split will reduce the number of outstanding common shares from approximately 30,764,540 to about 1,538,227. No fractional shares will be issued, and stockholders will receive a cash payment in lieu of any fractional shares based on the closing sales price on August 1, 2025 [1].

Despite the reverse stock split, Acurx Pharmaceuticals continues to face significant financial challenges. The company has reported no revenue growth over various periods, with total revenue growth metrics remaining at zero. This lack of revenue generation highlights the company's reliance on external funding and its inability to generate cash flow from operations [3].

Operating Margin: 0%
Net Margin: 0%
EBITDA Margin: 0%

The company's financial health is further indicated by a Piotroski F-Score of 3, suggesting poor business operations and raising concerns about its financial strength and operational efficiency [3].

Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics targeting Gram-positive bacterial infections. The company's innovative approach and pipeline include antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that block the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death [1].

The company's lead product candidate, ibezapolstat, for the treatment of Clostridioides difficile infection, is Phase 3 ready and plans to begin international clinical trials next year subject to obtaining appropriate financing. The company's preclinical pipeline also includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections) and a parallel development program for treatment of inhaled anthrax [1].

Acurx Pharmaceuticals faces numerous risks and uncertainties, including whether ibezapolstat will benefit from the QIDP designation, advance through the clinical trial process on a timely basis, and receive approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies [1].

References
[1] https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-announces-reverse-stock-split-302518702.html
[2] https://www.nasdaq.com/articles/acurx-approves-1-20-reverse-stock-split-regain-nasdaq-compliance
[3] https://www.gurufocus.com/news/3022769/acurx-acxp-implements-1for20-reverse-stock-split-to-maintain-nasdaq-listing